Clinical Study

Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies

Figure 3

Kaplan-Meier estimate of freedom from cellular rejection. (a) Survival free from cellular rejection graded ≥3A/2R on surveillance endomyocardial biopsies performed during year 1 in patients with or without pretransplant HLA ab. (b) Survival free from cellular rejection graded ≥3A/2R on surveillance endomyocardial biopsies performed after year 1 in patients with or without pretransplant HLA ab.
519680.fig.003a
(a)
519680.fig.003b
(b)